Viatris Inc (VTRS): Operating Cash Flow
$2.32B
Year ended 2025-12-31
$2.33B
Trailing 12 months to 2026-06-30
-8.3%
3-year compound annual growth
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $2.32B | +0.6% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $2.30B | -20.6% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $2.90B | -3.3% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $3.00B | n/c | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $3.02B | +144.9% | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | $1.23B | -31.7% | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | $1.80B | -23.0% | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $2.34B | n/a | 2021-03-01, From 2018-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Viatris Inc (VTRS) | 2025-12-31 | $2.32B | +0.6% |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $4.98B | +12.6% |
| Vertex Pharmaceuticals Inc (VRTX) | 2025-12-31 | $3.63B | n/m |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $1.65B | +32.2% |
| Bausch Health Companies Inc. (BHC) | 2025-12-31 | $1.40B | -12.3% |
| Zoetis Inc. (ZTS) | 2025-12-31 | $2.90B | -1.7% |
| Organon & Co. (OGN) | 2025-12-31 | $700.00M | -25.5% |
| BeOne Medicines Ltd. (ONC) | 2025-12-31 | $1.13B | n/m |
| Elanco Animal Health Inc (ELAN) | 2025-12-31 | $560.00M | +3.5% |
Compare VTRS, REGN, VRTX, TEVA side by side · Screen every company in Pharmaceutical Preparations ↗